GLOBAL BLOOD THERAPEUTICS Stock News

Grant proposals accepted through July 29, 2022 Grant proposals accepted through July 29, 2022

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

SOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on June 1, 2022, the compensation committee of GBT’s boar

Conference call and webcast will include data presented at EHA 2022 and business and R&D updates

Conference call and webcast will include data presented at EHA 2022 and business and R&D updates

Global Blood's (GBT) Oxbryta is approved for treating sickle cell disease. The recent label expansion nod to Oxbryta is a positive.

Global Blood Therapeutics (GBT) reports y/y wider loss in Q1. Revenues witness a rise.

Global Blood Therapeutics, Inc. (NASDAQ:GBT ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Steven Immergut – Senior Vice Preside, Head-Corporate Communications and In

Global Blood (GBT) delivered earnings and revenue surprises of 2.33% and 2.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Global Blood Therapeutics is enjoying strong fundamental improvement amid the biotech bear market.

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock?

The past year was a transformational time for Global Blood Therapeutics. The company was able to report growth for its flagship product, Oxbryta, in the face of COVID-19 headwinds.

ROCKVILLE, Md., March 08, 2022 (GLOBE NEWSWIRE) -- The American Kidney Fund is pleased to announce the addition of five new members to its national volunteer Board of Trustees, all of whom have worked throughout their careers to advance health equity and advocate for improvements to health care and quality of life for all those affected by kidney disease. The new members who joined the board effective March 4 are: Kenneth R. Bridges, MD, Principal Medical Director and Vice President of Medical Affairs at Global Blood Therapeutics. Dr. Bridges has worked for many years to address issues of health disparities; he also serves as the founder and director of the International Sickle Cell Anemia Foundation. Oliver T. Brooks, MD, Chief Medical Officer at Watts Healthcare Corporation and Medical Director for L.A. Care Health Plan. Dr. Brooks, immediate past president of the National Medical Association, is a nationally recognized leader on health care in communities of color and has participated in AKF''s congressional briefing and Unknown Causes of Kidney Disease Summit .

Global Blood Therapeutics (NASDAQ: GBT ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 3 1 0 0 Last 30D 0 0 1 0 0 1M Ago 0 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 2 0 0 0 These 4 analysts have an average price target of $56.5 versus the current price of Global Blood Therapeutics at $29.15, implying upside. Below is a summary of how these 4 analysts rated Global Blood Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive … Full story available on Benzinga.com